Taken together, our present data suggested that BRD4 inhibition by JQ1 in patients with sunitinib-sensitive and -resistant ccRCC may improve their prognosis and suppress cancer progression by comprehensively suppressing the expression of these oncogenes. This evidence concerns the gene BRD4 and cancer.